C ٦

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940		OMB Number:         3235-0287           Estimated average burden         hours per response:         0.5
1. Name and Address of Reporting Person <sup>*</sup> Kendall Keith J	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Aquestive Therapeutics, Inc.</u> [ AQST ]	(Check all applicable X Director	10% Owner
(Last)(First)(Middle)C/O AQUESTIVE THERAPEUTICS, INC.30 TECHNOLOGY DRIVE	3. Date of Earliest Transaction (Month/Day/Year) 05/31/2020	A below)	below) EO and President
(Street) WARREN NJ 07059	<ul> <li>4. If Amendment, Date of Original Filed (Month/Day/Year)</li> </ul>	Line) X Form filed	t/Group Filing (Check Applicable by One Reporting Person by More than One Reporting
(City) (State) (Zip)			

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)
Common Stock	05/31/2020		<b>M</b> <sup>(1)</sup>		14,572	A	\$ <mark>0</mark>	695,456	D	
Common Stock	05/31/2020		<b>F</b> <sup>(2)</sup>		6,492	D	\$4.87	688,964	D	

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(3-, Paris,,,,,														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	\$0	05/31/2020		M <sup>(1)</sup>			14,572	05/31/2020	(3)	Common Stock	14,572	\$0	0	D	

## **Explanation of Responses:**

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

2. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability.

3. There are no expiration dates on RSUs.

**Remarks:** 

/s/ Robert Arnold, as Attorney-06/01/2020 In-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.